Get notified when SEPN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Cmo (new) — Chief Medical Officer is leaving for another opportunity as the company advances two clinical programs; successor search underway with advisory transition planned.
Septerna reports Q1 2026 results with $522M cash, Phase 1 SEP-631 data, and CMO departure
Filed May 11, 2026 · Period ending May 11, 2026 · ~1 min read
Key Changes
-
high
Q1 2026 net loss narrowed to $8.6M from $21.5M year-ago on $26.5M collaboration revenue (vs. $0.2M prior year); $522M cash extends runway into 2029
Exhibit 99.1 verify on EDGAR → -
high
Phase 1 data for SEP-631 (MRGPRX2 inhibitor) showed good tolerability, once-daily dosing profile, and dose-dependent wheal suppression; Phase 2b trial in chronic urticaria planned for H2 2026
Exhibit 99.1 verify on EDGAR → -
high
Phase 1 trial initiated for SEP-479 (oral PTH1R agonist) in hypoparathyroidism; data expected late 2026 or early 2027
Exhibit 99.1 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (UNF 10-Q) is open in full — no account needed.
Partner
Trade SEPN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 9, 2026 · How we verify